SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(O'Meara E)
 

Search: WFRF:(O'Meara E) > (2020-2024) > Cardiac Myosin Acti...

  • Teerlink, John R.San Francisco VA Med Ctr, CA 94143 USA; Univ Calif San Francisco, CA 94143 USA (author)

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • Waltham, MA, United States :MASSACHUSETTS MEDICAL SOC,2021
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-173405
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-173405URI
  • https://doi.org/10.1056/NEJMoa2025797DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|AmgenAmgen; Cytokinetics; ServierServier
  • Among patients with heart failure and a reduced ejection fraction, those who received the cardiac myosin activator omecamtiv mecarbil had a lower incidence of a composite of heart-failure events or cardiovascular death at a median of 22 months than those who received placebo. Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. Methods We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. Results During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P=0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. Conclusions Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, ; EudraCT number, 2016-002299-28.)

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Diaz, RafaelEstudios Clin Latino Amer, Argentina (author)
  • Felker, G. MichaelDuke Univ, NC 27706 USA; Duke Clin Res Inst, NC USA; Natl & Kapodistrian Univ Athens, Greece (author)
  • McMurray, John J. V.British Heart Fdn, England (author)
  • Metra, MarcoUniv Brescia, Italy (author)
  • Solomon, Scott D.Brigham & Womens Hosp, MA 02115 USA (author)
  • Adams, Kirkwood F.Univ N Carolina, NC 27515 USA (author)
  • Anand, InderUniv Minnesota, MN USA (author)
  • Arias-Mendoza, AlexandraInst Nacl Cardiol, Mexico (author)
  • Biering-Sorensen, TorUniv Copenhagen, Denmark; Univ Copenhagen, Denmark (author)
  • Bohm, MichaelSaarland Univ, Germany (author)
  • Bonderman, DianaMed Univ Vienna, Austria (author)
  • Cleland, John G. F.Univ Glasgow, Scotland; Imperial Coll, England; Univ Nova Lisboa, Portugal (author)
  • Corbalan, RamonPontificia Univ Catolicica Chile, Spain (author)
  • Crespo-Leiro, Maria G.Univ A Coruna, Spain (author)
  • Dahlström, UlfLinköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Kardiologiska kliniken US(Swepub:liu)ulfda85 (author)
  • Echeverria, Luis E.Fdn Cardiovasc & Colombia, Colombia (author)
  • Fang, James C.Univ Utah, UT USA (author)
  • Filippatos, GerasimosNational and Kapodistrian University of Athens, Attikon University Hospital, Greece; Athens, Greece (author)
  • Fonseca, CandidaHospital S. Francisco Xavier, Centro Hospitalar Lisboa Ocidental, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal (author)
  • Goncalvesova, EvaComenius Univ, Slovakia (author)
  • Goudev, Assen R.Queen Giovanna Univ Hosp & Med Univ, Bulgaria (author)
  • Howlett, Jonathan G.Univ Calgary, Canada (author)
  • Lanfear, David E.Henry Ford Hosp, MI 48202 USA (author)
  • Li, JingChinese Acad Med Sci & Peking Union Med Coll, Peoples R China (author)
  • Lund, MayannaMiddlemore Hosp, New Zealand (author)
  • Macdonald, PeterSt Vincents Hosp Sydney, Australia (author)
  • Mareev, ViacheslavMoscow MV Lomonosov State Univ, Russia (author)
  • Momomura, Shin-ichiSaitama Citizens Med Ctr, Japan (author)
  • OMeara, EileenMontreal Heart Inst, Canada; Univ Montreal, Canada (author)
  • Parkhomenko, AlexanderSection of Cardiology, San Francisco Veterans Affairs Medical Center, School of Medicine, University of California, San Francisco, San Francisco, United States; Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom (author)
  • Ponikowski, PiotrWroclaw Med Univ, Poland (author)
  • Ramires, Felix J. A.Univ Sao Paulo, Brazil (author)
  • Serpytis, PranasVilnius Univ, Lithuania (author)
  • Sliwa, KarenUniv Cape Town, South Africa (author)
  • Spinar, JindrichSt Ann Hosp, Czech Republic; Masaryk Univ Brno, Czech Republic (author)
  • Suter, Thomas M.Univ Bern, Switzerland (author)
  • Tomcsanyi, JanosSt John God Hosp, Hungary (author)
  • Vandekerckhove, HansAZ St Lucas, Belgium (author)
  • Vinereanu, DragosUniv & Emergency Hosp, Romania (author)
  • Voors, Adriaan A.Univ Groningen, Netherlands (author)
  • Yilmaz, Mehmet B.Dokuz Eylul Univ, Turkey (author)
  • Zannad, FaiezSection of Cardiology, San Francisco Veterans Affairs Medical Center, School of Medicine, University of California, San Francisco, San Francisco, United States; Fundación Cardiovascular de Colombia, Floridablanca, Colombia (author)
  • Sharpsten, LucieAmgen Inc, CA USA (author)
  • Legg, Jason C.Amgen Inc, CA USA (author)
  • Varin, ClaireUniv Lorraine, France (author)
  • Honarpour, NarimonAmgen Inc, CA USA (author)
  • Abbasi, Siddique A.Amgen Inc, CA USA (author)
  • Malik, Fady I.Cytokinetics, CA USA (author)
  • Kurtz, Christopher E.Amgen Inc, CA USA (author)
  • San Francisco VA Med Ctr, CA 94143 USA; Univ Calif San Francisco, CA 94143 USAEstudios Clin Latino Amer, Argentina (creator_code:org_t)

Related titles

  • In:New England Journal of MedicineWaltham, MA, United States : MASSACHUSETTS MEDICAL SOC384:2, s. 105-1160028-47931533-4406

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view